CJC-1295 no DAC + Ipamorelin (GROW-H 10mg) Dosage Protocol
GHRH analog (CJC-1295 no DAC) + ghrelin GH secretagogue (Ipamorelin) in one blend — research-only; not FDA-approved.
Mix & measure CJC-1295 no DAC + Ipamorelin · 10 mg
Pre-filled with this protocol’s recommended BAC water and documented starting dose — edit any field to run your own numbers.
Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Full reconstitution guide → · Advanced calculator →
Dosing & Reconstitution Guide
One combined 10 mg vial — two dilution options for once-daily total-blend dosing
All doses below are stated as total blend (combined CJC-1295 no DAC + Ipamorelin). For a 10 mg blend the split is typically ~5 mg of each, though this is not labeled on the page; because both peptides share one vial, you cannot draw a single component separately. Run once daily on a 5-days-on / 2-days-off schedule to limit receptor desensitization.
Standard / Gradual Approach (3 mL = 3,333 mcg/mL)
Reconstitute: Add 3.0 mL bacteriostatic water to the 10 mg combined vial → 3,333 mcg/mL.
Typical daily range: 300–700 mcg total blend once daily, raised gradually across the cycle.
Easy measuring: At 3,333 mcg/mL, 1 unit ≈ 33.3 mcg on a U-100 syringe (units = mcg ÷ 33.33).
Weeks 1–4
300 mcg (1× daily)
~9 units (0.09 mL)
Weeks 5–8
500 mcg (1× daily)
~15 units (0.15 mL)
Weeks 9–12
600 mcg (1× daily)
~18 units (0.18 mL)
Weeks 13–16 (optional)
700 mcg (1× daily)
~21 units (0.21 mL)
Why CJC-1295 no DAC + Ipamorelin draws research interest
These are the directions researchers and the peptide community most often explore CJC-1295 no DAC + Ipamorelin for — so you know you’re in the right place. They describe what is being studied, not proven benefits, approved uses, or promised results.
GH & IGF-1 support
Investigated in research on stimulating pulsatile growth hormone release and downstream IGF-1; not approved for any therapeutic use.
Fat metabolism & lipolysis
Explored in preclinical research on how growth hormone secretagogues influence fat breakdown and body composition.
Recovery & tissue repair
Studied for growth hormone's role in connective tissue and muscle repair; investigational only, with no approved use.
Sleep quality
Investigated in early research on links between growth hormone secretagogues and slow-wave (deep) sleep.
Evidence ranges from early laboratory work to clinical trials depending on the use — the sections below cover the actual data and sources.
Quickstart Highlights
GROW-H is a single combined 10 mg blend vial pairing CJC-1295 no DAC (modified GRF 1-29, a short-acting GHRH analog) with Ipamorelin (a selective ghrelin/GHS-R agonist). Together a GHRH analog and a GHRP are intended to amplify the body’s own pulsatile growth-hormone release. Both are unapproved research chemicals — neither is FDA-approved — and the long-term body-composition, recovery and sleep benefits of this blend are not validated by controlled human trials. Presented for research and educational use only.
One 10 mg combined vial. Add 3.0 mL bacteriostatic water → 3,333 mcg/mL (Standard), or 2.0 mL → 5,000 mcg/mL (Advanced).
300–1,200 mcg total blend once daily, on a 5-days-on / 2-days-off schedule, titrated upward across the cycle.
Doses are total blend. At 3,333 mcg/mL, 1 unit ≈ 33.3 mcg; at 5,000 mcg/mL, 1 unit = 50 mcg on a U-100 syringe.